Olanzapine—which was first approved back in 1996—holds the distinction of being the most widely prescribed atypical antipsychotic for schizophrenia, where it’s used as a daily oral treatment.
Nevertheless, that daily regimen can make it hard for patients to stick with their medication schedule and raising the risk of instability and relapse, according to Teva.
BREAKING